Moderna developing mRNA vaccine for Lyme disease


A Lyme disease vaccine could be on its way soon, according to pharmaceutical company Moderna.
The company has announced two new mRNA vaccines in development that could prevent Lyme disease, marking the "first application of its mRNA technology to bacterial pathogens." The technology was used in creating the COVID-19 vaccine. Moderna also announced vaccine development plans for norovirus and RSV, which have both been spreading rapidly.
"Untreated, Lyme disease can be very serious," emergency physician and George Washington University professor Leana Wen told Axios. "Some people develop debilitating symptoms that really impact their lives." The disease comes from tick bites and can cause fever, chills, joint pain, and rashes, according to the Centers for Disease Control. If left untreated, the symptoms can be more severe including heart palpitations, arthritis, and facial palsy.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
There has only been one human Lyme disease vaccine that was ever available on the market and it was pulled in 2002 because "negative press coverage and limited awareness of the benefits of the vaccine decreased consumer demand for the vaccine," according to a 2007 study. However, there are approximately 120,000 reported cases of Lyme reported each year in the U.S. and Europe, and that number is rising due to climate change, per Axios.
Pfizer and its partner company Valneva also have a Lyme disease vaccine in the works that has shown promise, with the company saying it could get approved as early as 2025. It is still good practice to wear long sleeves and use insect repellant to prevent tick bites in the first place, but "after years of relying on such preventive steps, an age of advanced drugs and vaccines could be nigh," Axios writes.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
MAHA moms: the cohort of women backing RFK Jr.'s health agenda
The Explainer America's head health honcho has a flock of supporters spreading the MAHA message on social media
By Theara Coleman, The Week US Published
-
The banned pesticide poisoning Caribbean paradise
Under the radar Martinique and Guadeloupe have been rocked by soaring cancer rates amid other diagnoses
By Rebekah Evans, The Week UK Published
-
Poor sleep may make you more prone to believing conspiracy theories
Under the radar Catch z's for society
By Devika Rao, The Week US Published
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Bird flu: The viral threat pushing up egg prices
Feature
By The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published